44
Participants
Start Date
May 31, 2009
Primary Completion Date
November 30, 2012
Study Completion Date
November 30, 2012
plasmapheresis
Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
Bortezomib
Patients will receive bortezomib as described in protocol
Rituximab
Patients will receive rituximab as described in protocol
Methylprednisolone
Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
The Christ Hospital, Cincinnati
University of Cincinnati, Cincinnati
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
University of Cincinnati
OTHER